- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05201066
Étude de reconduction pour les patients qui ont terminé une étude antérieure sur le Sabatolimab (MBG453) sponsorisée par Novartis et qui sont jugés par l'investigateur comme bénéficiant d'un traitement continu avec le Sabatolimab.
Une étude ouverte, multicentrique et reconduite pour les patients qui ont déjà terminé une étude antérieure sur Sabatolimab (MBG453) sponsorisée par Novartis et qui sont jugés par l'investigateur comme bénéficiant d'un traitement continu avec Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79106
- Novartis Investigative Site
-
-
-
-
Victoria
-
Clayton, Victoria, Australie, 3168
- Novartis Investigative Site
-
-
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brésil, 88020-210
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Novartis Investigative Site
-
-
-
-
-
Tianjin, Chine, 300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Chine, 130021
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espagne, 08036
- Novartis Investigative Site
-
Madrid, Espagne, 28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Espagne, 08916
- Novartis Investigative Site
-
-
-
-
-
Toulouse, France, 31059
- Novartis Investigative Site
-
-
-
-
-
Alexandroupoli, Grèce, 681 00
- Novartis Investigative Site
-
Pátrai, Grèce, 265 04
- Novartis Investigative Site
-
-
-
-
BS
-
Brescia, BS, Italie, 25123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Italie, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italie, 16132
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italie, 20162
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italie, 00133
- Novartis Investigative Site
-
-
-
-
-
Fukushima, Japon, 9601295
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaisie, 59100
- Novartis Investigative Site
-
-
-
-
-
Zurich, Suisse, 8091
- Novartis Investigative Site
-
-
-
-
-
Prague, Tchéquie, 128 08
- Novartis Investigative Site
-
-
-
-
-
Izmir, Turquie (Türkiye), 35100
- Novartis Investigative Site
-
-
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
Autres noms:
Solution for subcutaneous injection or intravenous infusion |
|
Expérimental: sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
Autres noms:
Solution for intravenous infusion |
|
Expérimental: sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
Autres noms:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
Expérimental: sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
Autres noms:
Solution for intravenous infusion Solution for intravenous infusion
Autres noms:
|
|
Expérimental: sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
Autres noms:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
Expérimental: sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: 5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
Délai: 5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of exposure to sabatolimab
Délai: 5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Tumeurs par type histologique
- Maladies hématologiques
- Leucémie myéloïde
- Maladies myélodysplasiques-myéloprolifératives
- Maladies de la moelle osseuse
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie myélomonocytaire chronique
- Syndromes myélodysplasiques
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Acides nucléiques, nucléotides et nucléosides
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Composés Aza
- Nucléosides
- Ribonucléosides
- Décitabine
- Azacitidine
- vénitoclax
- combinaison de médicaments à la décitabine et à la cédazuridine
- Spartalizumab
- sabatolimab
Autres numéros d'identification d'étude
- CMBG453B12206B
- 2021-004422-30 (Numéro EudraCT)
- 2024-515281-14-00 (Identificateur de registre: EU CTIS)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .